$48.61
+0.76 (+1.59%)
TEM News4 articles
Tempus AI Upsizes Convertible Debt to $400M, Eyes Loan Repayment
Tempus AI priced $400M in 0% convertible senior notes, using proceeds to repay $307.7M in loans. Shares fell 7.6% premarket despite strong Q1 revenue growth.
Tempus AI Faces Pivotal May with Q1 Results and Inaugural Investor Day
Tempus AI reports Q1 results May 5 and holds its first investor day May 29, with Merck CEO highlighting the partnership. Stock trades near $55.44 with a $9.7B market cap.
Tempus AI Partners with USC Health System, Unlocking Access to 1.5 Million Annual Visits
Tempus AI Inc. partners with USC's Keck School of Medicine to deploy its molecular testing and trial-matching platform across a health system seeing 1.5 million patient visits each year.
Tempus AI Stock Drops on USC Partnership as Cancer Data Strategy Faces Scrutiny
Tempus AI shares fell 7.3% after announcing a partnership with USC to deploy its molecular testing and AI tools across the health system, covering over 1.5 million annual patient visits.